Claes Lundberg

Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase.

Helicure AB develops and manufactures vaccines. It operates as a biotech company that focuses on developing vaccines for prevention of gastric cancer caused by Helicobacter pylori, through active immunisation in infected patients with persistent dyspepsia. The company was founded by Thomas Borén and Lennart Hammarström in 2005 and is headquartered in Umea, Sweden.

Melacure Therapeutics AB develops and manufactures pharmaceutical products. Its products are used for treatment of obesity, irritable bowel syndrome, inflammation, and sexual dysfunction. The company was founded in 1998 and is located in Uppsala, Sweden.

Innoventus Project AB engages in the development and commercialization of ideas, projects, and patents in life science. The company was founded on October 6, 2001 and is headquartered in Uppsala, Sweden.

Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ.